Idaho Medicaid Pharmacy and Therapeutics (P&T) Committee

Public Testimony Guidelines

Background

The Idaho Medicaid Pharmacy and Therapeutics Committee reviews evidence-based clinical information to make recommendations for medication coverage of specific drug classes to the Idaho Department of Health and Welfare. Recommendations are based primarily on objective evaluations of the relative safety, effectiveness, and clinical outcomes of a specific medication in comparison with other therapeutically interchangeable alternative medications. Evaluation can include information submitted through public testimony. Public testimony fits generally into two categories, clinical experience from a health care provider or a Medicaid participant or scientific information provided by pharmaceutical manufacturers or their representatives.

Public Testimony Processes

- Clinical experience, either from a provider or a Medicaid participant
    - Clinical experience information is available to the Committee through letters received by the Committee and/or by oral testimony given during the public comment period of the P&T meeting. Providers and participants will not be restricted from relating clinical experience, other than the time constraints needed to accommodate speakers during the 60-minute public comment period.
    - Written submissions should be submitted to a designated Medicaid representative (currently Tami Eide):

      Idaho Medicaid
      Pharmacy & Therapeutics Committee
      Attention: Tami Eide, Pharm.D.
      3232 Elder Street
      Boise, Idaho 83705

      eidet@dhw.idaho.gov
    - Oral testimony sign up occurs between 30 minutes prior to the meeting and 30 minutes after the meeting is called to order.
- Scientific information provided by pharmaceutical manufacturers or their representatives

- Pharmaceutical manufacturer scientists or representatives must submit in writing any proposed testimony to be considered for review by the P&T Committee Membership.
- Pharmaceutical manufacturer representatives who wish to submit scientific information should review the information already available to Committee members. This information is publicly available on the Idaho Medicaid P&T website www.medicaidpharmacy.idaho.gov). Pharmaceutical representatives may submit scientific information not already available to Committee members through Provider Synergies, the Drug Effectiveness Review Project (DERP) and/or other standard drug information sources. Submitted information is most useful if reviewed in conjunction with drug class reviews that Committee members are already studying. Submission of scientific information, therefore, is required to be submitted to the Idaho Medicaid Pharmacy Unit in writing at least **20** days prior to the meeting so that if approved, it can be carefully considered by Committee members prior to the meeting.

- There may be times when scientific information may become available less than 20 days prior to the meeting. In such cases, special requests may be made to the Medicaid Pharmacy Unit for submission to the P&T Chairman for approval or rejection.

- All scientific information submitted will be restricted to new information only. New information is considered to be: **(1) new studies released since the last review, excluding placebo only studies or** (**2) New product or new indication information not included in the Provider Synergies' Therapeutics Class Reviews or the DERP Reviews posted on the P&T Website.**

- All scientific information submitted must include a one page cover sheet of 250 words or less that summarizes the key points and directs the Committee members to the key areas of the submitted information for consideration. Page number, paragraphs and line numbers should be cited.

- <u>Material submitted for review shall be limited to only new information meeting the requirements above.</u> Product

monographs and dossiers, P&T Committee briefs, extensive bibliographies, or similar inclusions will not be considered.

- Written submissions should be submitted to the Chairman of the P&T Committee through a designated Medicaid representative (currently Tami Eide). Written submissions may either be mailed or e-mailed.

  Idaho Medicaid
  Pharmacy & Therapeutics Committee
  Attention: Tami Eide, Pharm.D.
  3232 Elder Street
  Boise, Idaho 83705

  e-mail: eidet@dhw.idaho.gov

- The P&T Committee chairman or his designee will review the submitted information to determine if it meets the new information guidelines noted above. The Department will then advise submitters of acceptance or rejection of the information at least 10 days prior to the meeting. If submitted information is rejected, the P&T Committee Chairman or his designee shall provide a written summary to the submitter detailing the reasons for rejection. The Department will disseminate accepted materials to P&T Committee members for review.

- All submitted written testimony and scientific information provided by a pharmaceutical manufacturer shall be posted to the P&T Committee website. Testimony accepted for P&T Committee review will be designated as such.

- A company who has submitted information accepted for review has the option of having a designated representative available at the P&T meeting to present the accepted testimony. Such testimony shall not exceed five (5) minutes including questions. Such time limitation may be extended at the discretion of the chairman.

- If a company has reason to believe that during the P&T meeting that submitted information was misrepresented to or by committee members or that facts were mis-

stated, they may submit an appeal in writing detailing their concerns by 5:00 PM of the next business day following the P&T Committee meeting. The concerns shall be presented concisely in less than 250 words and delivered to the Medicaid Pharmacy Unit (contact information above) for delivery to the Idaho Medicaid P&T Committee Chair. This written appeal and supporting information considered by the committee members and shall be posted on the P&T website. This process is limited to inaccuracies, mis-statements, or misrepresentations concerning submitted information. Any perceived inaccuracies of DERP or Provider Synergies drug class reviews should be routed through their established processes.

Orig. 5/20/2011
Update: 11/9/11
Effective: 1/1/2012